Human study · Supplements / medicine · 8 Sept 2026
Early statin use linked to 15% lower dementia risk
Source: ScienceDaily
What the research found
Study (observational). Using Danish registers of 132,585 people newly diagnosed with type 2 diabetes (2006–2019), Ternhamar and colleagues reported at ESC Congress 2026 and in The Lancet Regional Health – Europe that starting statins within a year of diagnosis associated with a 15% lower relative dementia risk over 10 years versus no statin; starting at 1–5 years associated with 10% lower risk. Median follow-up 7.1 years; 2.7% developed dementia. Clone-censor-weight methods emulate a trial but cannot prove causation. Statins are prescription cholesterol medicines, not a dementia cure or a supplement.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34